People Science has announced the publication of a study conducted in partnership with Mimio Health evaluating a novel daily supplement formulation designed to selectively activate biological pathways associated with fasting (such as autophagy and metabolic repair) without requiring dietary restriction.
Instead of trying to mimic fasting behaviours, the formulation targeted the underlying molecular signals by utilising a proprietary blend of biomolecules, which includes spermidine, nicotinamide, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA).
Published in Nature Scientific Reports, the clinical trial marks an important step forward in the scientific exploration of nutrient-sensing metabolic biology.
During an eight-week period, the intervention produced statistically significant improvements in multiple cardiometabolic biomarkers compared with placebo. These included Total Cholesterol, LDL, Oxidised LDL and Fasting Glucose.
Participants who received the active formulation reported increased satiety, suggesting better appetite regulation in older individuals with elevated metabolic risk.
The supplement was also found to be safe and well-tolerated for daily use.
Taken together, the findings provide clinical evidence that components of fasting biology can be engaged through targeted nutritional intervention—opening new possibilities for studying and refining metabolic repair pathways in populations for whom fasting is impractical or contraindicated.
"Validating a metabolic intervention like this typically requires a controlled clinical setting, but we wanted to prove efficacy in the real world," said Dr Chris Rhodes, CEO of Mimio Health.
"People Science allowed us to conduct a rigorous, gold-standard trial directly in participants' homes."
The data we gathered not only confirmed our mechanism of action but also showed that our formulation can deliver the benefits of fasting to the population that needs it most.
Beyond the biological outcomes, the study highlights the growing role of decentralised clinical trials in advancing complex metabolic science.
Using People Science's Chloe platform, the trial successfully conducted remote biosampling, daily-dosing adherence and biomarker analysis entirely in participants' homes.
This demonstrated that high-quality clinical research can be conducted outside traditional research centres without compromising rigour.
"This work shows that we can investigate sophisticated biological mechanisms in real-world conditions and still meet the highest scientific standards," said Dr Noah Craft, co-CEO of People Science.
By combining decentralised infrastructure with biomarker-driven endpoints, we're able to move more quickly from hypothesis to evidence and, importantly, to identify where the science should go next.
The publication establishes a clinically validated starting point for future investigations into fasting-associated biology, including longer-term studies, mechanistic refinement and exploration across additional metabolic populations.
Rather than serving as a conclusion, the findings signal the emergence of a more precise, accessible approach to studying metabolic resilience and repair.